Quarterly growth stalled due to weather, supply chain and staffing, but the promise of new product introductions in H2 will return healthy growth to the Trauma Market.
The Q222 Trauma Market was impacted by several conditions that contributed to decelerating growth, such as a reduced demand for trauma-related devices, supply chain challenges and facility staffing hurdles. The WW Trauma Market growth slowed sequentially in Q2, down compared to Q122’s growth. The US Trauma Market fared a bit better than WW results, but also experienced a sequential slump compared to Q122. For the first half of 2022, the US Trauma Market was up +3.5% YTD growth compared to H121.
Among the many topics covered in detail in our comprehensive Q222 Trauma Market Recap* are:
- Complete Q222 Trauma Overview and Highlights
- SmartTRAK's Expert Analysis and Insights
- All Company News including Revenues, Data, Charts and Shares
- Mergers & Acquisitions
- Q222 Trauma Regulatory Highlights
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below. 
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution for the Life Sciences Industry that provides breaking updates on pertinent company news, potential treatments and guidance, international survey results, statistical analysis by country, studies, trial results, financial impact and more. All subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to learn more about SmartTRAK, just click here.
